Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 10:20 PM
Ignite Modification Date: 2025-12-25 @ 7:53 PM
NCT ID: NCT04499235
Description: None
Frequency Threshold: 0
Time Frame: 5 weeks
Study: NCT04499235
Study Brief: A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Mometasone Furoate + AKST4290 Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached. Mometasone furoate: Topical mometasone furoate AKST4290: Oral AKST4290 0 None 0 5 2 5 View
Mometasone Furoate + Placebo Subjects will receive mometasone furoate concurrently with placebo until disease control is reached. Mometasone furoate: Topical mometasone furoate Placebo: Oral placebo 1 None 1 1 0 1 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
COVID-19 SYSTEMATIC_ASSESSMENT Infections and infestations None View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Rash SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders None View
Blood potassium decreased SYSTEMATIC_ASSESSMENT Investigations None View